<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683692</url>
  </required_header>
  <id_info>
    <org_study_id>20-001308</org_study_id>
    <nct_id>NCT04683692</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Use of The Sentinel Device During Atrial Fibrillation Ablation</brief_title>
  <official_title>A Pilot Randomized Study of the Use of The Sentinel Device for Cerebral Protection During Atrial Fibrillation Ablation: MRI Imaging and Laboratory Sub-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are determining whether the use of the Sentinel cerebral protection device during&#xD;
      atrial fibrillation ablation will affect the occurrence of new cerebral infarcts in brain&#xD;
      MRI. We are also studying if laboratory tests can be used to predict the rate of cerebral&#xD;
      infarction and microbleeds in patients undergoing atrial fibrillation (AF) ablation&#xD;
      procedures with and without use of the Sentinel Device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients currently participating in the research study titled: &quot;A Pilot Randomized Study of&#xD;
      the Use of the Sentinel Device for Cerebral Protection during Atrial Fibrillation Ablation&quot;&#xD;
      will be asked to participate in this sub-study to collect additional MRI and laboratory data&#xD;
      to support the main study. This study will assess the number, size and volume of new cerebral&#xD;
      emboli in protected territories detected using MRI of the brain within 7 days after AF&#xD;
      ablation in patients treated with the Sentinel device compared to controls not receiving the&#xD;
      Sentinel device, and to assess if change in blood inflammatory markers is associated with&#xD;
      silent cerebral lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parent Study Design: Patients undergoing clinically indicated catheter ablation for AF in the parent study will be randomized 2:1 to two arms: (1) cerebral protection with the Sentinel device and (2) control group without cerebral protection</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>For both the parent study and the sub-study, participants and investigators will be unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>New cerebral infarcts</measure>
    <time_frame>day 1 to 7 after atrial fibrillation ablation</time_frame>
    <description>Total number of new cerebral infarcts in the protected territories detected on brain MRI after ablation in the Sentinel device group vs control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in high sensitivity CRP (hs-CRP)</measure>
    <time_frame>baseline 1 - 30 days prior to ablation, days 1 - 7 after atrial fibrillation ablation</time_frame>
    <description>High sensitivity CRP (hs-CRP) measured in mg/L to detect changes in peripheral markers of inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in interleukin-6 (IL-6)</measure>
    <time_frame>baseline 1 - 30 days prior to ablation, days 1 - 7 after atrial fibrillation ablation</time_frame>
    <description>Interleukin-6 measured in pg/ml to detect changes in peripheral markers of inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in NT-proBNP</measure>
    <time_frame>baseline 1 - 30 days prior to ablation, days 1 - 7 after atrial fibrillation ablation</time_frame>
    <description>NT-proBNP measured in pg/ml to detect changes in tissue damage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in high sensitivity troponin</measure>
    <time_frame>baseline 1 - 30 days prior to ablation, days 1 - 7 after atrial fibrillation ablation</time_frame>
    <description>High sensitivity troponin measure in ng/mL to detect changes in tissue damage</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cerebral protection with the Sentinel device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received the Sentinel device in the parent study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group without cerebral protection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who did not received the Sentinel device in the parent study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation</description>
    <arm_group_label>Cerebral protection with the Sentinel device</arm_group_label>
    <arm_group_label>Control group without cerebral protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Testing</intervention_name>
    <description>Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation</description>
    <arm_group_label>Cerebral protection with the Sentinel device</arm_group_label>
    <arm_group_label>Control group without cerebral protection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over the age of 18 years undergoing radiofrequency or cryoballoon ablation&#xD;
             for AF who provide informed consent will be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe peripheral arterial disease that precludes deployment of Sentinel device&#xD;
&#xD;
          -  Unable to undergo MRI brain due to the presence of an MRI noncompatible implanted&#xD;
             device&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent.&#xD;
&#xD;
          -  Known history of dementia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ammar Killu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ammar M Killu, MBBS</last_name>
    <phone>507-538-6325</phone>
    <email>killu.ammar@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ammar M. Killu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

